Evidence map›Paper›PMID 41459501›Full record

ArticleFrontiers in immunology2025

IL-33 and IL-3 synergistically induce CD25 expression on human basophils without functional IL-2 signaling: a potential marker of severe COVID-19.

Sruthi Vijaya Retnakumar, Suraj Chandrabhan Singh, Camille Chauvin, Jagadeesh Bayry

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sruthi Vijaya RetnakumarInstitut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Paris, France.
Suraj Chandrabhan SinghDepartment of Biological Sciences & Engineering, Indian Institute of Technology Palakkad, Palakkad, India.
Camille ChauvinInstitut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Paris, France.
Jagadeesh BayryInstitut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD25 (IL-2 receptor alpha chain) is a key component of the high-affinity receptor for the IL-2 cytokine and regulates the proliferation, survival, and differentiation of immune cells. The expression of CD25 has been demonstrated in basophils of patients with allergic diseases such as asthma. Previous studies have shown that IL-3 priming leads to increased CD25 expression in basophils. However, other potential stimuli that can regulate the CD25 expression on basophils and their possible biological consequences remain poorly understood. Here, we demonstrate that the IL-33 cytokine, a critical driver of type 2 immunity and allergic inflammation, significantly upregulates CD25 expression on IL-3-primed human basophils. Despite high levels of CD25 expression and its ability to capture IL-2 cytokine, basophils fail to express CD122 (IL-2 receptor beta chain), resulting in the absence of downstream signal transducer and activator of transcription 5 (STAT5) phosphorylation and lack of IL-2-mediated survival signals. The binding of IL-2 to basophil-derived CD25 appears to be transient since co-culturing with regulatory T cells (Treg cells) demonstrates that IL-2 remains accessible to Treg cells, enhancing their viability. Furthermore, an analysis of publicly available single-cell RNA sequencing data from COVID-19 patients revealed increased gene expressions of

Indexed as

BasophilsCOVID-19Interleukin-2 Receptor alpha SubunitInterleukin-3Interleukin-33SARS-CoV-2BiomarkersCells, CulturedHumansInterleukin-2Signal TransductionT-Lymphocytes, RegulatoryBiomarkersIL2RA protein, humanIL33 protein, humanIL3 protein, humanInterleukin-2Interleukin-2 Receptor alpha SubunitInterleukin-3Interleukin-33basophilsCD25COVID-19IL-2IL-3IL-33TregType 2 immunity

Identifiers

PMID41459501
PMCPMC12738815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.